These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 38197085)

  • 1. Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review.
    Velásquez PA; Hernandez JC; Galeano E; Hincapié-García J; Rugeles MT; Zapata-Builes W
    Clin Pharmacol; 2024; 16():1-25. PubMed ID: 38197085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.
    Mohamed K; Yazdanpanah N; Saghazadeh A; Rezaei N
    Bioorg Chem; 2021 Jan; 106():104490. PubMed ID: 33261845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products.
    Rafiq A; Jabeen T; Aslam S; Ahmad M; Ashfaq UA; Mohsin NUA; Zaki MEA; Al-Hussain SA
    Molecules; 2023 Jun; 28(12):. PubMed ID: 37375415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.
    Deshpande RR; Tiwari AP; Nyayanit N; Modak M
    Eur J Pharmacol; 2020 Nov; 886():173430. PubMed ID: 32758569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections.
    Dos Santos Nascimento IJ; de Aquino TM; da Silva-Júnior EF
    Curr Med Chem; 2021; 28(15):2887-2942. PubMed ID: 32787752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2.
    Kandeil A; Mostafa A; Kutkat O; Moatasim Y; Al-Karmalawy AA; Rashad AA; Kayed AE; Kayed AE; El-Shesheny R; Kayali G; Ali MA
    Pathogens; 2021 Jun; 10(6):. PubMed ID: 34203977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic.
    Khadka S; Yuchi A; Shrestha DB; Budhathoki P; Al-Subari SMM; Ziad Alhouzani TM; Anwar Butt I
    Altern Ther Health Med; 2020 Aug; 26(S2):100-107. PubMed ID: 32827400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Data of Current Therapies for SARS-CoV-2.
    Anastasiou IA; Eleftheriadou I; Tentolouris A; Tsilingiris D; Tentolouris N
    Curr Med Chem; 2020; 27(27):4542-4548. PubMed ID: 32400323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19.
    Kumar S; Zhi K; Mukherji A; Gerth K
    Viruses; 2020 Apr; 12(5):. PubMed ID: 32357553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.
    Gudadappanavar AM; Benni J
    J Basic Clin Physiol Pharmacol; 2020 Sep; 31(6):. PubMed ID: 32924964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug repurposing approach to fight COVID-19.
    Singh TU; Parida S; Lingaraju MC; Kesavan M; Kumar D; Singh RK
    Pharmacol Rep; 2020 Dec; 72(6):1479-1508. PubMed ID: 32889701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
    Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
    ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
    Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
    J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.